4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
#SABCS24 Day 1 Highlights #CommunityOnc:
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social
1/5
📌Immunotherapy for Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine
nejm.org/doi/full/10.10…
“Early-stage triple-negative breast cancer has an identity that is defined by what it needs, not what it lacks”
@oncoalert.bsky.social #OncoAlertAF #BreatCancer #Editorial #KN522
